SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(ROSEN B) "

Sökning: WFRF:(ROSEN B)

  • Resultat 61-70 av 347
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  •  
62.
  •  
63.
  •  
64.
  • Cicardi, M., et al. (författare)
  • Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema
  • 2010
  • Ingår i: New England Journal of Medicine. - 0028-4793. ; 363:6, s. 532-541
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist. METHODS In two double-blind, randomized, multicenter trials, we evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was given once, subcutaneously, at a dose of 30 mg. The primary end point was the median time to clinically significant relief of symptoms. RESULTS A total of 56 and 74 patients underwent randomization in the FAST-1 and FAST-2 trials, respectively. The primary end point was reached in 2.5 hours with icatibant versus 4.6 hours with placebo in the FAST-1 trial (P=0.14) and in 2.0 hours with icatibant versus 12.0 hours with tranexamic acid in the FAST-2 trial (P<0.001). In the FAST-1 study, 3 recipients of icatibant and 13 recipients of placebo needed treatment with rescue medication. The median time to first improvement of symptoms, as assessed by patients and by investigators, was significantly shorter with icatibant in both trials. No icatibant-related serious adverse events were reported. CONCLUSIONS In patients with hereditary angioedema having acute attacks, we found a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificant benefit of icatibant as compared with placebo in the other trial with regard to the primary end point. The early use of rescue medication may have obscured the benefit of icatibant in the placebo trial. (Funded by Jerini; ClinicalTrials.gov numbers, NCT00097695 and NCT00500656.)
  •  
65.
  •  
66.
  •  
67.
  •  
68.
  • Wang, Li-San, et al. (författare)
  • Rarity of the Alzheimer Disease-Protective APP A673T Variant in the United States.
  • 2015
  • Ingår i: JAMA neurology. - : American Medical Association (AMA). - 2168-6157 .- 2168-6149. ; 72:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Recently, a rare variant in the amyloid precursor protein gene (APP) was described in a population from Iceland. This variant, in which alanine is replaced by threonine at position 673 (A673T), appears to protect against late-onset Alzheimer disease (AD). We evaluated the frequency of this variant in AD cases and cognitively normal controls to determine whether this variant will significantly contribute to risk assessment in individuals in the United States.
  •  
69.
  •  
70.
  • Bayley, PJ, et al. (författare)
  • 2013 SYR Accepted Poster Abstracts
  • 2013
  • Ingår i: International journal of yoga therapy. - 1531-2054. ; 23:1, s. 32-53
  • Tidskriftsartikel (refereegranskat)
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 347
Typ av publikation
tidskriftsartikel (289)
konferensbidrag (40)
bokkapitel (7)
forskningsöversikt (5)
rapport (2)
annan publikation (1)
visa fler...
doktorsavhandling (1)
visa färre...
Typ av innehåll
refereegranskat (308)
övrigt vetenskapligt/konstnärligt (37)
populärvet., debatt m.m. (1)
Författare/redaktör
Donadelli, M. (42)
Ellinghaus, F. (42)
Hill, J. C. (42)
Jia, J. (42)
Leite, M. A. L. (42)
Milov, A. (42)
visa fler...
Nakamura, T. (42)
Vrba, V. (42)
Li, X. (42)
Ruzicka, P. (42)
Grau, N. (42)
Liu, H. (42)
Kim, Y. J. (42)
Stenlund, Evert (41)
Proissl, M. (41)
Fusayasu, T (41)
Lebedev, A. (41)
Thomas, T. L. (41)
Bathe, S. (41)
Boyle, K (41)
Park, S. K. (41)
Sukhanov, A. (41)
Averbeck, R. (41)
Awes, T. C. (41)
Baumann, C. (41)
Buesching, H. (41)
Chujo, T. (41)
Enokizono, A. (41)
Glenn, A. (41)
Gunji, T. (41)
Hamagaki, H. (41)
Hamblen, J. (41)
Horaguchi, T. (41)
Inaba, M. (41)
Kang, J. H. (41)
Khanzadeev, A. (41)
Kim, D. J. (41)
Kwon, Y. (41)
Lee, K. S. (41)
Mao, Y. (41)
Miake, Y. (41)
Newby, J. (41)
Okada, K. (41)
Ozawa, K. (41)
Park, W. J. (41)
Pereira, H. (41)
Rak, J. (41)
Read, K. F. (41)
Reygers, K. (41)
Samsonov, V. (41)
visa färre...
Lärosäte
Karolinska Institutet (127)
Lunds universitet (112)
Göteborgs universitet (51)
Uppsala universitet (36)
Linköpings universitet (24)
Kungliga Tekniska Högskolan (21)
visa fler...
Stockholms universitet (19)
Umeå universitet (15)
Chalmers tekniska högskola (14)
Högskolan i Halmstad (10)
Sveriges Lantbruksuniversitet (6)
Luleå tekniska universitet (5)
Örebro universitet (4)
Högskolan i Skövde (3)
Mittuniversitetet (2)
Linnéuniversitetet (2)
Högskolan i Borås (2)
RISE (2)
Jönköping University (1)
Malmö universitet (1)
Högskolan Dalarna (1)
visa färre...
Språk
Engelska (339)
Svenska (7)
Tyska (1)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (105)
Medicin och hälsovetenskap (103)
Teknik (34)
Samhällsvetenskap (10)
Humaniora (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy